Sanofi-aventis has posted business net income of EUR2.43bn, or E1.86 per diluted share, compared to EUR2.21bn, or EUR1.70 per diluted share, for the prior year period. Business operating income was EUR3.3bn, compared to EUR3.1bn for the year ago period.
For the first quarter of 2010, pharmaceuticals division revenue was EUR6.4bn, compared to EUR6.5bn for the prior year period. Vaccines division revenue was EUR944m, compared to EUR627m for the year ago period.
Sanofi-aventis expects growth in Business EPS at constant exchange rates to be between two and 5% in 2010.
Christopher Viehbacher, CEO of sanofi-aventis, said: “During this first quarter, our growth platforms delivered double-digit growth enhanced by recent targeted acquisitions and A/H1N1 vaccine sales. This good start to the year which benefited from A/H1N1 puts us on track to deliver our 2010 guidance.
“In parallel, we also added a strong US pillar to our Consumer Health Care business with the acquisition of Chattem and took a significant step towards the creation of a new global leader in Animal Health.”